HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b-Reference-Cited by-同舟云学术

HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b

Published:2012-11-16 Issue:1 Volume:12 Page:
ISSN:1471-230X
Container-title:BMC Gastroenterology
language:en
Short-container-title:BMC Gastroenterol

Author:

Pellicelli Adriano M, ,Romano Mario,Stroffolini Tommaso,Mazzoni Ettore,Mecenate Fabrizio,Monarca Roberto,Picardi Antonio,Bonaventura Maria Elena,Mastropietro Cristina,Vignally Pascal,Andreoli Arnaldo,Marignani Massimo,D’Ambrosio Cecilia,Miglioresi Lucia,Nosotti Lorenzo,Mitidieri Olga,Gentilucci Umberto Vespasiani,Puoti Claudio,Barbaro Giuseppe,Barlattani Angelo,Furlan Caterina,Barbarini Giorgio

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,General Medicine

Link

http://link.springer.com/article/10.1186/1471-230X-12-162/fulltext.html

Reference22 articles.

1. McHutchison JG, Everson GT, Gordon SC, et al: PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009, 360: 1827-1838. 10.1056/NEJMoa0806104.

2. Kwo PY, Lawitz EJ, McCone J, et al: SPRINT-1 investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010, 376: 705-716. 10.1016/S0140-6736(10)60934-8.

3. Fried MW, Shiffman ML, Reddy K, et al: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002, 347: 975-982. 10.1056/NEJMoa020047.

4. Hadziyannis SJ, Sette H, Morgan TR, et al: PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004, 140: 346-355.

5. Cheng WS, Roberts SK, McCaughan G: Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. J Hepatol. 2010, 53: 616-623. 10.1016/j.jhep.2010.04.024.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Increase in the Prevalence of Clinically Relevant Resistance-Associated Substitutions in Four Direct-Acting Antiviral Regimens: A Study Using GenBank HCV Sequences;Pathogens;2024-08-09

2. PAM-free diagnostics with diverse type V CRISPR-Cas systems;2024-05-03

3. Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients;World Journal of Gastroenterology;2022-12-07

4. Epidemiology, mutational landscape and staging of hepatocellular carcinoma;Chinese Clinical Oncology;2021-01

5. Hepatitis C–Related Mortality Among American Indian/Alaska Native Persons in the Northwestern United States, 2006-2012;Public Health Reports;2019-11-25